The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study).
The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study).
复制标题
治疗前淋巴细胞与单核细胞比率 (LMR) 可预测 TAS-102 和贝伐单抗联合治疗的转移性结直肠癌的治疗效果和预后（TAS-CC3 研究）。
DOI：
--
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Koda K
中科院分区：
文献类型：
--
作者：
Matsuda A;Yoshida Y;Kamiyama H;Kosugi C;Yoshida H;Ishibashi K;Ihara K;Takahashi M;Kuramochi H;Fukazawa A;Sonoda H;Yoshimatsu K;Yamaguchi S;Ishida H;Hasegawa S;Yamada T;Sakamoto K;Koda K
